Successful delivery of genistein-miRNA-29b-loaded hybrid nanoparticles (GMLHN) will significantly inhibit NSCLC tumor by downregulating essential oncoproteins, phosphorylated AKT (pAKT), phosphorylated phosphoinositide-3 kinase (p-PI3K), myeloid cell leukemia sequence 1 (MCL 1) and DNA methyltransferase 3B (DNMT3B). The gene discussed is AKT1; the disease is neoplasm.